Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Andrew Smith as CFO and a member of the Executive Management team, effective April 1, 2020.

Andrew Smith joins Santhera with broad experience in corporate and operational finance in the pharmaceutical and biotech industry, most recently as CFO and COO at Allecra Therapeutics GmbH. Previously, Andrew was CFO of NASDAQ-listed Sucampo Pharmaceuticals Inc., based in the US. During that time, he was involved in a number of capital market transactions in the value of approximately USD 600 million. Prior to that, he held various financial and operations roles focusing on business improvement and transformation where he has gained significant exposure to European and US markets in different organizations with a focus on start-ups, spinoffs and growth. Andrew is a Fellow of the Chartered Institute of Management Accountants and a Chartered Global Management Accountant. He studied business and accounting at Liverpool John Moores University and Durham University Business School.

Dario Eklund, Chief Executive Officer of Santhera, said: “Andrew is a results-driven and entrepreneurial CFO with a very broad financial and operations background. With his proven track record in all aspects of corporate finance both in Europe and the US, the Board of Directors and I believe that Andrew possesses the expertise and leadership capabilities to strategically and effectively run our finance operations, thereby advancing Santhera towards sustainable growth. I extend a warm welcome to Andrew and I am looking forward to working with him.”

“I am excited to join Santhera at the current time where the company expects several near-term inflection points,” said Andrew Smith, designated CFO. “Together with the experienced senior leadership team including the Company’s new CEO and the support by the Board of Directors, I am looking forward to actively contributing to the Company’s strategic growth plans.”